🟢 Biovie is trading 5% up despite broader market weakness

Biovie is trading 5.18% up at $2.03 on September 14, 2026, with no confirmed company-specific catalyst identified.

• No new company-specific announcement dated September 14 was identified.
• BioVie’s investor-relations page lists its latest release on September 8, regarding FDA engagement for the Parkinson’s Phase 3 program.
• Major indexes are lower, suggesting a stock-specific trading rebound or speculative activity, but no confirmed catalyst directly explains the move.